Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up

Mario Facchini, Tiziana Varisco, Oscar Bonazzi, Silvia G. Priori, Valeria Songa, Peter J. Schwartz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose). Antiarrhythmic response was evaluated at 3 days and 3, 6, 12, 18, and 24 months. The mean follow-up was 25 ± 14 months (range 3 to 52). Four patients (19%) were excluded from efficacy analysis because of spontaneous decrease in baseline arrhythmia observed after 12 months of therapy. Effective arrhythmia suppression at both Hoter monitoring and during exercise stress testing was maintained in 14 of 17 patients (82%). Mean frequency of premature ventricular contractions remained reduced by more than 95% throughout the follow-up. Five patients discontinued therapy between 3 and 18 months because of drug ineffectiveness (three patients, 18%) or side effects (two patients, 12%). In 12 patients (71%) long-term efficacy and tolerance were demonstrated. In no case was aggravation of arrhythmia or adverse cardiac effects observed. Side effects (5% to 29% of patients during follow-up) were usually minor and easily abolished by dosage reduction. In patients with chronic ventricular arrhythmias, flecainide maintained a favorable ratio between efficacy and side effects during a 2-year follow-up.

Original languageEnglish
Pages (from-to)1258-1264
Number of pages7
JournalAmerican Heart Journal
Volume117
Issue number6
DOIs
Publication statusPublished - 1989

Fingerprint

Flecainide
Cardiac Arrhythmias
Safety
Ventricular Premature Complexes
Exercise

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias : A two-year follow-up. / Facchini, Mario; Varisco, Tiziana; Bonazzi, Oscar; Priori, Silvia G.; Songa, Valeria; Schwartz, Peter J.

In: American Heart Journal, Vol. 117, No. 6, 1989, p. 1258-1264.

Research output: Contribution to journalArticle

@article{8e90c579c6ec4d1b8b308b8f4c31e80e,
title = "Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up",
abstract = "The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose). Antiarrhythmic response was evaluated at 3 days and 3, 6, 12, 18, and 24 months. The mean follow-up was 25 ± 14 months (range 3 to 52). Four patients (19{\%}) were excluded from efficacy analysis because of spontaneous decrease in baseline arrhythmia observed after 12 months of therapy. Effective arrhythmia suppression at both Hoter monitoring and during exercise stress testing was maintained in 14 of 17 patients (82{\%}). Mean frequency of premature ventricular contractions remained reduced by more than 95{\%} throughout the follow-up. Five patients discontinued therapy between 3 and 18 months because of drug ineffectiveness (three patients, 18{\%}) or side effects (two patients, 12{\%}). In 12 patients (71{\%}) long-term efficacy and tolerance were demonstrated. In no case was aggravation of arrhythmia or adverse cardiac effects observed. Side effects (5{\%} to 29{\%} of patients during follow-up) were usually minor and easily abolished by dosage reduction. In patients with chronic ventricular arrhythmias, flecainide maintained a favorable ratio between efficacy and side effects during a 2-year follow-up.",
author = "Mario Facchini and Tiziana Varisco and Oscar Bonazzi and Priori, {Silvia G.} and Valeria Songa and Schwartz, {Peter J.}",
year = "1989",
doi = "10.1016/0002-8703(89)90404-3",
language = "English",
volume = "117",
pages = "1258--1264",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias

T2 - A two-year follow-up

AU - Facchini, Mario

AU - Varisco, Tiziana

AU - Bonazzi, Oscar

AU - Priori, Silvia G.

AU - Songa, Valeria

AU - Schwartz, Peter J.

PY - 1989

Y1 - 1989

N2 - The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose). Antiarrhythmic response was evaluated at 3 days and 3, 6, 12, 18, and 24 months. The mean follow-up was 25 ± 14 months (range 3 to 52). Four patients (19%) were excluded from efficacy analysis because of spontaneous decrease in baseline arrhythmia observed after 12 months of therapy. Effective arrhythmia suppression at both Hoter monitoring and during exercise stress testing was maintained in 14 of 17 patients (82%). Mean frequency of premature ventricular contractions remained reduced by more than 95% throughout the follow-up. Five patients discontinued therapy between 3 and 18 months because of drug ineffectiveness (three patients, 18%) or side effects (two patients, 12%). In 12 patients (71%) long-term efficacy and tolerance were demonstrated. In no case was aggravation of arrhythmia or adverse cardiac effects observed. Side effects (5% to 29% of patients during follow-up) were usually minor and easily abolished by dosage reduction. In patients with chronic ventricular arrhythmias, flecainide maintained a favorable ratio between efficacy and side effects during a 2-year follow-up.

AB - The long-term efficacy and safety of flecainide (100 to 200 mg twice a day) were evaluated in 21 patients with high-grade, chronic ventricular arrhythmias who responded to and tolerated flecainide at a preliminary evaluation (200 mg, single oral dose). Antiarrhythmic response was evaluated at 3 days and 3, 6, 12, 18, and 24 months. The mean follow-up was 25 ± 14 months (range 3 to 52). Four patients (19%) were excluded from efficacy analysis because of spontaneous decrease in baseline arrhythmia observed after 12 months of therapy. Effective arrhythmia suppression at both Hoter monitoring and during exercise stress testing was maintained in 14 of 17 patients (82%). Mean frequency of premature ventricular contractions remained reduced by more than 95% throughout the follow-up. Five patients discontinued therapy between 3 and 18 months because of drug ineffectiveness (three patients, 18%) or side effects (two patients, 12%). In 12 patients (71%) long-term efficacy and tolerance were demonstrated. In no case was aggravation of arrhythmia or adverse cardiac effects observed. Side effects (5% to 29% of patients during follow-up) were usually minor and easily abolished by dosage reduction. In patients with chronic ventricular arrhythmias, flecainide maintained a favorable ratio between efficacy and side effects during a 2-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0024338004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024338004&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(89)90404-3

DO - 10.1016/0002-8703(89)90404-3

M3 - Article

C2 - 2499170

AN - SCOPUS:0024338004

VL - 117

SP - 1258

EP - 1264

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -